Aarti Pharmalabs Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/7tjyum1xzf839laoofo0c4oj.pdf

Key Takeaways


Xanthine Derivatives: Volume Offsets Price, Mix Shift Underway

Gogri: "Aarti Pharma Labs is positioned in such a way that it has a global size, it has a risk mitigation strategy, which doesn't depend on China at all."

CDMO/CMO: Pipeline Converting, Capacity Ready

Gogri: "We can do backward integrated work also so, we can do four, five, six stages in-house. So we are able to give a proposal to innovators that we will try to do maximum steps in India only and having least dependency on China."

API & Intermediates: Volume-Led Growth, Regulated-Market Tilt

Gogri: "In the generic market, I have never seen prices go up even in rupee terms, except the product become extremely genericized, and you are at the rock bottom."

Margins: Record Quarter, Sustainability Questions

Gogri: "We are hopeful that we are able to replicate these kind of performance in future quarters as well. But of course, we can't have a certain linearity there will be ups and downs, but overall, we will see a growth going."

Capacity & Infrastructure: Two Large Projects Advancing


Guidance & Commitments

CommitmentSpecificsTimeline
FY25 EBITDA growthMay exceed previously provided 10–12% growth guidanceFY25 (verifiable at Q4)
CDMO/CMO FY25 revenueWill exceed last year's Rs.170 crore in the current quarterQ4 FY25
CDMO/CMO FY26 revenueWill be "significantly higher" than FY25, independent of shifted ordersFY26
Xanthine capacity expansion5,000 to 9,000 MT in two phasesH1 and H2 FY26
Xanthine utilization target90% capacity utilizationFY27
Atali Phase-1 commissioningCommissioning in Q1, ramp-up toward end of FY26Q1 FY26 / end FY26
Second solar project (9 MW DC)Commissioning for Gujarat unitsQ2 FY26
Solid multi-fuel boilersStarting at two Maharashtra plantsQ4 FY25
Xanthine regulatory filingsDMF and EUGMP CEP from Tarapur unit threeCurrent quarter (Q4 FY25)
Long-term guidance resetFull budgeting, strategic review, yearly and three-year guidanceQ4 FY25 concall

Key Metrics

MetricQ3 FY25
Consolidated revenue₹538 cr, +20% YoY
EBITDA₹129 cr, +34% YoY
Profit after tax₹74 cr, +40% YoY
Standalone EBITDA margin~24%, 200–300 bps higher than previous two quarters
FY25 EBITDA growth guidanceExceeding 10–12% previously guided
Xanthine derivatives revenue share44% of turnover
API and intermediates revenue share42% of turnover; sub-segment: 48% regulated, 40% ROW, 12% non-reg
CDMO/CMO revenue share13% of turnover
CDMO/CMO active projects56 projects, 28 commercial and 28 in development
CDMO/CMO customers21 customers, 2 added in Q3
API quarterly revenue run rate₹203 cr, up from ₹150 cr a year ago
API capacity utilization~75%, with 10% additional capacity being added
Xanthine spot market volume share30–40% of total volume
Vapi plant shutdown impactLower than 5% of turnover and 2% of profit
Ganesh Polychem EBITDA contribution (50% share)₹13 cr in Q3, vs ₹9 cr last quarter